Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference

BIO CEO & Investor Conference 2015

MARLBOROUGH, Mass.--()--Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 17th Annual BIO CEO and Investor Conference on Monday, February 9, 2015 at 9:30 a.m. ET in New York City.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Ocata website, www.ocata.com. A replay of the webcast will be archived on Ocata's website for 90 days following the presentation.

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.

Contacts

Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com

Ocata Therapeutics, Inc.